

Note: This document is a translation of the original Japanese version and provided for reference purposes only. In the event of any discrepancy between the Japanese original and this English translation, the Japanese original shall prevail.

Press Release



ASKA Pharmaceutical Holdings Selected for “Highly Improved Sustainability Disclosure” by GPIF’s Asset Managers Entrusted with Domestic Equity Investment

TOKYO, March 25, 2026 – ASKA Pharmaceutical Holdings Co., Ltd. (TSE: 4886, Head Office: Minato-ku, Tokyo/ President, Representative Director: Sohta Yamaguchi, hereinafter “ASKA”) is pleased to announce that it has been selected for the first time as one of the companies with “Highly Improved Sustainability Disclosure from the Perspective of Materiality” by external asset managers entrusted with domestic equity investment of the Government Pension Investment Fund (GPIF).

This selection recognizes companies that have made particularly significant improvements in their sustainability disclosures based on material issues that are important to corporate management.

ASKA was highly evaluated for the qualitative enhancement of its sustainability disclosures, including its Integrated Report, which led to this selection.

Through its Integrated Report, “ASKA HD REPORT,” which integrates both financial and non-financial information, ASKA has been disclosing its business strategy in conjunction with its sustainability initiatives.

Going forward, ASKA will continue to promote more advanced disclosure of information based on material issues with an emphasis on dialogue with stakeholders, and strive to further improve its medium- to long-term corporate value.

(Reference)

■ “Highly Improved Sustainability Disclosure from the Perspective of Materiality” by GPIF’s Asset Managers Entrusted with Domestic Equity Investment * Japanese version only

https://www.gpif.go.jp/esg-stw/20260317_excellent_sustainability_disclosure.pdf

■ ASKA Pharmaceutical Holdings Co., Ltd. Integrated Report: “ASKA HD REPORT 2025”

https://www.aska-pharma-hd.co.jp/english/invest/library/aska_report.html

Media Contacts

ASKA Pharmaceutical Holdings Co., Ltd.

Corporate Planning Department

Tel: +81-3-5484-8366

Email: kouhou@aska-pharma.co.jp